Selected research
Market Structure
Global Platinum-based Anticancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Platinum-based Anticancer Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Platinum-based Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Platinum-based Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Platinum-based Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Platinum-based Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Platinum-based Anticancer Drugs include Teva, Sun Pharmaceutical, Qilu Pharmaceutical, Nanjing Pharmaceutical Factory, Mylan, Luoxin, Jiangsu Aosaikang Pharmaceutical, Jiangsu Hengrui Medicine and Fresenius Kabi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Platinum-based Anticancer Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Platinum-based Anticancer Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Platinum-based Anticancer Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Platinum-based Anticancer Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Platinum-based Anticancer Drugs Segment by Company
Teva
Sun Pharmaceutical
Qilu Pharmaceutical
Nanjing Pharmaceutical Factory
Mylan
Luoxin
Jiangsu Aosaikang Pharmaceutical
Jiangsu Hengrui Medicine
Fresenius Kabi
Yakult honsha
Taj Pharmaceuticals
Sanofi-Aventis
Lingnan Pharmacy
Hospira(Pfizer)
Hisun Pharmaceutical
Hansoh Pharma
Dr Reddy's laboratories
Platinum-based Anticancer Drugs Segment by Type
Oxaliplatin
Carboplatin
Nedaplatin
Cisplatin
Others
Platinum-based Anticancer Drugs Segment by Application
Esophageal Cancer
Breast Cancer
Osteosarcoma
Testicular Cancer
NSCLC
Other
Platinum-based Anticancer Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Platinum-based Anticancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Platinum-based Anticancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Platinum-based Anticancer Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Platinum-based Anticancer Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Platinum-based Anticancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Platinum-based Anticancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Platinum-based Anticancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Oxaliplatin
- Carboplatin
- Nedaplatin
- Cisplatin
- Others
Applications
- Esophageal Cancer
- Breast Cancer
- Osteosarcoma
- Testicular Cancer
- NSCLC
- Other
Companies covered
- Teva
- Sun Pharmaceutical
- Qilu Pharmaceutical
- Nanjing Pharmaceutical Factory
- Mylan
- Luoxin
- Jiangsu Aosaikang Pharmaceutical
- Jiangsu Hengrui Medicine
- Fresenius Kabi
- Yakult honsha
- Taj Pharmaceuticals
- Sanofi-Aventis
- Lingnan Pharmacy
- Hospira(Pfizer)
- Hisun Pharmaceutical
- Hansoh Pharma
- Dr Reddy's laboratories
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Platinum-based Anticancer Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Platinum-based Anticancer Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Platinum-based Anticancer Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Platinum-based Anticancer Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Platinum-based Anticancer Drugs Market Dynamics
- 2.1 Platinum-based Anticancer Drugs Industry Trends
- 2.2 Platinum-based Anticancer Drugs Industry Drivers
- 2.3 Platinum-based Anticancer Drugs Industry Opportunities and Challenges
- 2.4 Platinum-based Anticancer Drugs Industry Restraints
3 Platinum-based Anticancer Drugs Market by Manufacturers
- 3.1 Global Platinum-based Anticancer Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Platinum-based Anticancer Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Platinum-based Anticancer Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Platinum-based Anticancer Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Platinum-based Anticancer Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Platinum-based Anticancer Drugs Manufacturers, Product Type & Application
- 3.7 Global Platinum-based Anticancer Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Platinum-based Anticancer Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Platinum-based Anticancer Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Platinum-based Anticancer Drugs Tier 1, Tier 2, and Tier 3
4 Platinum-based Anticancer Drugs Market by Type
- 4.1 Platinum-based Anticancer Drugs Type Introduction
- 4.1.1 Oxaliplatin
- 4.1.2 Carboplatin
- 4.1.3 Nedaplatin
- 4.1.4 Cisplatin
- 4.1.5 Others
- 4.2 Global Platinum-based Anticancer Drugs Sales by Type
- 4.2.1 Global Platinum-based Anticancer Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Platinum-based Anticancer Drugs Sales by Type (2021-2032)
- 4.2.3 Global Platinum-based Anticancer Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Platinum-based Anticancer Drugs Revenue by Type
- 4.3.1 Global Platinum-based Anticancer Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Platinum-based Anticancer Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Platinum-based Anticancer Drugs Revenue Market Share by Type (2021-2032)
5 Platinum-based Anticancer Drugs Market by Application
- 5.1 Platinum-based Anticancer Drugs Application Introduction
- 5.1.1 Esophageal Cancer
- 5.1.2 Breast Cancer
- 5.1.3 Osteosarcoma
- 5.1.4 Testicular Cancer
- 5.1.5 NSCLC
- 5.1.6 Other
- 5.2 Global Platinum-based Anticancer Drugs Sales by Application
- 5.2.1 Global Platinum-based Anticancer Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Platinum-based Anticancer Drugs Sales by Application (2021-2032)
- 5.2.3 Global Platinum-based Anticancer Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Platinum-based Anticancer Drugs Revenue by Application
- 5.3.1 Global Platinum-based Anticancer Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Platinum-based Anticancer Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Platinum-based Anticancer Drugs Revenue Market Share by Application (2021-2032)
6 Global Platinum-based Anticancer Drugs Sales by Region
- 6.1 Global Platinum-based Anticancer Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Platinum-based Anticancer Drugs Sales by Region (2021-2032)
- 6.2.1 Global Platinum-based Anticancer Drugs Sales by Region (2021-2026)
- 6.2.2 Global Platinum-based Anticancer Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Platinum-based Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Platinum-based Anticancer Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Platinum-based Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Platinum-based Anticancer Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Platinum-based Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Platinum-based Anticancer Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Platinum-based Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Platinum-based Anticancer Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Platinum-based Anticancer Drugs Revenue by Region
- 7.1 Global Platinum-based Anticancer Drugs Revenue by Region
- 7.1.1 Global Platinum-based Anticancer Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Platinum-based Anticancer Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Platinum-based Anticancer Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Platinum-based Anticancer Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Platinum-based Anticancer Drugs Revenue (2021-2032)
- 7.2.2 North America Platinum-based Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Platinum-based Anticancer Drugs Revenue (2021-2032)
- 7.3.2 Europe Platinum-based Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Platinum-based Anticancer Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Platinum-based Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Platinum-based Anticancer Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Platinum-based Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Teva
- 8.1.1 Teva Company Information
- 8.1.2 Teva Business Overview
- 8.1.3 Teva Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Teva Platinum-based Anticancer Drugs Product Portfolio
- 8.1.5 Teva Recent Developments
- 8.2 Sun Pharmaceutical
- 8.2.1 Sun Pharmaceutical Company Information
- 8.2.2 Sun Pharmaceutical Business Overview
- 8.2.3 Sun Pharmaceutical Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Sun Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio
- 8.2.5 Sun Pharmaceutical Recent Developments
- 8.3 Qilu Pharmaceutical
- 8.3.1 Qilu Pharmaceutical Company Information
- 8.3.2 Qilu Pharmaceutical Business Overview
- 8.3.3 Qilu Pharmaceutical Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Qilu Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio
- 8.3.5 Qilu Pharmaceutical Recent Developments
- 8.4 Nanjing Pharmaceutical Factory
- 8.4.1 Nanjing Pharmaceutical Factory Company Information
- 8.4.2 Nanjing Pharmaceutical Factory Business Overview
- 8.4.3 Nanjing Pharmaceutical Factory Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Nanjing Pharmaceutical Factory Platinum-based Anticancer Drugs Product Portfolio
- 8.4.5 Nanjing Pharmaceutical Factory Recent Developments
- 8.5 Mylan
- 8.5.1 Mylan Company Information
- 8.5.2 Mylan Business Overview
- 8.5.3 Mylan Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Mylan Platinum-based Anticancer Drugs Product Portfolio
- 8.5.5 Mylan Recent Developments
- 8.6 Luoxin
- 8.6.1 Luoxin Company Information
- 8.6.2 Luoxin Business Overview
- 8.6.3 Luoxin Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Luoxin Platinum-based Anticancer Drugs Product Portfolio
- 8.6.5 Luoxin Recent Developments
- 8.7 Jiangsu Aosaikang Pharmaceutical
- 8.7.1 Jiangsu Aosaikang Pharmaceutical Company Information
- 8.7.2 Jiangsu Aosaikang Pharmaceutical Business Overview
- 8.7.3 Jiangsu Aosaikang Pharmaceutical Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Jiangsu Aosaikang Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio
- 8.7.5 Jiangsu Aosaikang Pharmaceutical Recent Developments
- 8.8 Jiangsu Hengrui Medicine
- 8.8.1 Jiangsu Hengrui Medicine Company Information
- 8.8.2 Jiangsu Hengrui Medicine Business Overview
- 8.8.3 Jiangsu Hengrui Medicine Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Jiangsu Hengrui Medicine Platinum-based Anticancer Drugs Product Portfolio
- 8.8.5 Jiangsu Hengrui Medicine Recent Developments
- 8.9 Fresenius Kabi
- 8.9.1 Fresenius Kabi Company Information
- 8.9.2 Fresenius Kabi Business Overview
- 8.9.3 Fresenius Kabi Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Fresenius Kabi Platinum-based Anticancer Drugs Product Portfolio
- 8.9.5 Fresenius Kabi Recent Developments
- 8.10 Yakult honsha
- 8.10.1 Yakult honsha Company Information
- 8.10.2 Yakult honsha Business Overview
- 8.10.3 Yakult honsha Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Yakult honsha Platinum-based Anticancer Drugs Product Portfolio
- 8.10.5 Yakult honsha Recent Developments
- 8.11 Taj Pharmaceuticals
- 8.11.1 Taj Pharmaceuticals Company Information
- 8.11.2 Taj Pharmaceuticals Business Overview
- 8.11.3 Taj Pharmaceuticals Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Taj Pharmaceuticals Platinum-based Anticancer Drugs Product Portfolio
- 8.11.5 Taj Pharmaceuticals Recent Developments
- 8.12 Sanofi-Aventis
- 8.12.1 Sanofi-Aventis Company Information
- 8.12.2 Sanofi-Aventis Business Overview
- 8.12.3 Sanofi-Aventis Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Sanofi-Aventis Platinum-based Anticancer Drugs Product Portfolio
- 8.12.5 Sanofi-Aventis Recent Developments
- 8.13 Lingnan Pharmacy
- 8.13.1 Lingnan Pharmacy Company Information
- 8.13.2 Lingnan Pharmacy Business Overview
- 8.13.3 Lingnan Pharmacy Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Lingnan Pharmacy Platinum-based Anticancer Drugs Product Portfolio
- 8.13.5 Lingnan Pharmacy Recent Developments
- 8.14 Hospira(Pfizer)
- 8.14.1 Hospira(Pfizer) Company Information
- 8.14.2 Hospira(Pfizer) Business Overview
- 8.14.3 Hospira(Pfizer) Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Hospira(Pfizer) Platinum-based Anticancer Drugs Product Portfolio
- 8.14.5 Hospira(Pfizer) Recent Developments
- 8.15 Hisun Pharmaceutical
- 8.15.1 Hisun Pharmaceutical Company Information
- 8.15.2 Hisun Pharmaceutical Business Overview
- 8.15.3 Hisun Pharmaceutical Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 Hisun Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio
- 8.15.5 Hisun Pharmaceutical Recent Developments
- 8.16 Hansoh Pharma
- 8.16.1 Hansoh Pharma Company Information
- 8.16.2 Hansoh Pharma Business Overview
- 8.16.3 Hansoh Pharma Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.16.4 Hansoh Pharma Platinum-based Anticancer Drugs Product Portfolio
- 8.16.5 Hansoh Pharma Recent Developments
- 8.17 Dr Reddy's laboratories
- 8.17.1 Dr Reddy's laboratories Company Information
- 8.17.2 Dr Reddy's laboratories Business Overview
- 8.17.3 Dr Reddy's laboratories Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.17.4 Dr Reddy's laboratories Platinum-based Anticancer Drugs Product Portfolio
- 8.17.5 Dr Reddy's laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Platinum-based Anticancer Drugs Value Chain Analysis
- 9.1.1 Platinum-based Anticancer Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Platinum-based Anticancer Drugs Production Mode & Process
- 9.2 Platinum-based Anticancer Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Platinum-based Anticancer Drugs Distributors
- 9.2.3 Platinum-based Anticancer Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst